Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals Inc

Health CarePharmaceuticals & Biotechnology
  • Price (USD)8.90
  • Today's Change-0.06 / -0.67%
  • Shares traded492.54k
  • 1 Year change120.30%
  • Beta3.0955
Data delayed at least 15 minutes, as of Jan 19 2017 21:00 GMT.
More ▼

Events & Activity

  • PGNX:NSQ price moved over -1.23% to 8.85
  • PGNX:NSQ price falls below 15-day moving average to 8.85 at 09:30 GMT
  • PGNX:NSQ price rises above 15-day moving average to 8.94 at 15:25 GMT
  • PGNX:NSQ price falls below 15-day moving average to 8.87 at 14:14 GMT

Key statistics

On Thursday, Progenics Pharmaceuticals Inc (PGNX:NSQ) closed at 8.90, -8.96% below its 52-week high of 9.78, set on Dec 27, 2016.
52-week range
3.61Feb 09 20169.78Dec 27 2016
Markit short selling activity
Previous close8.90
Average volume928.71k
Shares outstanding70.05m
Free float68.89m
P/E (TTM)56.98
Market cap623.46m USD
EPS (TTM)0.1562 USD
Data delayed at least 15 minutes, as of Jan 19 2017 21:00 GMT.
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.